Circulating Expression of the Myocardial Infarction (MI)-related Long Noncoding RNAs (lncRNAs) in Type 2 Diabetes (T2D)

2020 ◽  
Vol 229 ◽  
pp. 169
Author(s):  
Nurruzanna Ismail ◽  
Siti Aishah Sulaiman ◽  
Noraidatulakma Abdullah ◽  
Nor Azian Abdul Murad ◽  
Rahman Jamal
Keyword(s):  
Myocardial Infarction ◽  
Type 2 Diabetes ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas

scholarly journals Circulating long noncoding RNAs H19 and GAS5 are associated with type 2 diabetes but not with diabetic retinopathy: A preliminary study

2020 ◽  
Author(s):  
Manal S. Fawzy ◽  
Ahmed A. Abdelghany ◽  
Eman A. Toraih ◽  
Abeer M. Mohamed
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Retinopathy ◽  
Plasma Levels ◽  
Expression Profiles ◽  
Noncoding Rnas ◽  
Early Response ◽  
Long Noncoding Rnas ◽  
Expression Levels ◽  
Lncrna Expression

Recently, a wide range of biological and pathological roles of long noncoding RNAs (lncRNAs) have been discovered. However, the potential role of circulating lncRNAs H19 and GAS5 in type 2 diabetes mellitus (T2DM) and diabetic retinopathy (DR) is not clear. Here, we assessed the plasma levels of H19 and GAS5 lncRNAs in T2DM patients with/without DR and evaluated if H19 and GAS5 pre-treatment plasma levels are a predictor of early response to a single aflibercept dose in DR subgroup. Plasma lncRNA expression profiles of 119 T2DM patients (66 with DR and 53 without DR) and 110 healthy controls were determined by quantitative reverse transcription PCR. The association of lncRNA expression profiles with clinical features and aflibercept early response in DR patients was investigated. Relative H19 expression levels were significantly increased in T2DM group (including DR and non-DR subgroups) vs. controls, while GAS5 levels were decreased in T2DM group (p < 0.001). There was no significant difference in H19 and GAS5 expression levels between DR and non-DR subgroups. H19 and GAS5 expression profiles were not significantly correlated with clinical parameters or response to aflibercept therapy in DR subgroup. Our findings indicate that the circulating lncRNAs H19 and GAS5 may be associated with T2DM prevalence but may not have an important diagnostic/prognostic role in DR or early response to aflibercept intravitreal injection in DR patients. Large-scale transcriptomic studies are warranted to validate our results and investigate other lncRNA candidates in T2DM.

scholarly journals The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults

2020 ◽  
Vol 2020 ◽  
pp. 1-12 ◽  
Author(s):  
Zhang Pengyu ◽  
Yan Yan ◽  
Fu Xiying ◽  
Yang Maoguang ◽  
Li Mo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Target Genes ◽  
Autoimmune Diabetes ◽  
Expression Profiles ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Latent Autoimmune Diabetes

Background. Long noncoding RNAs (lncRNAs) were previously found to be closely related to the pathogenesis of diabetes. Objectives. To reveal the differentially expressed lncRNAs and messenger RNAs (mRNAs) involved in type 2 diabetes mellitus (T2DM) and latent autoimmune diabetes in adults (LADA) and predict the lncRNA target genes to derive their expression profiles for the diagnosis of T2DM and LADA and their differential diagnosis. Methods. Twelve venous blood samples were collected from T2DM patients, LADA patients, and nondiseased subjects to obtain total RNAs. After removing rRNA from total RNAs to establish the desired library for sequencing, quality control and quantification analyses were carried out. The fragments per kilobase of exon model per million reads mapped (FPKM) of lncRNAs were calculated to construct the gene expression profiles of lncRNAs and mRNAs. Fold changes (fold change: 2.0) and p values (p value: 0.05, FPKM ≥ 0.1) were calculated, and then differentially expressed lncRNAs and mRNAs were screened. To obtain the significantly coexpressed lncRNA-mRNA pairs, the lncRNA target genes were deduced according to the association between adjacent sites. Results. Compared to nondiseased controls, 68,763 versus 28,523 lncRNAs and 133 versus 1035 mRNAs were significantly upregulated and significantly downregulated, respectively, in T2DM patients. For LADA patients, 68,748 versus 28,538 lncRNAs and 219 versus 805 mRNAs were significantly upregulated and significantly downregulated, respectively, relative to nondiseased controls. Compared to T2DM patients, 74,207 versus 23,079 lncRNAs and 349 versus 137 mRNAs were significantly upregulated and significantly downregulated, respectively, in LADA patients. Based on the correlation analysis, seven lncRNA-mRNA pairs (BTG2, A2M, HECTD4, MBTPS1, DBH, FLVCR1, and NCBP2) were significantly coexpressed, and two lncRNAs (ENST00000608916 and ENST00000436373) were newly discovered. Conclusion. Significant differences in lncRNA expression were discovered among the three groups. Furthermore, after predicting lncRNA expression profiles, GO/KEGG pathway analysis could deduce the target gene function.

Urinary Long Noncoding RNAs (lncRNAs) as Biomarkers for Diabetic Nephropathy in Malaysian Type 2 Diabetes Patients

2020 ◽  
Vol 229 ◽  
pp. 169-170
Author(s):  
Tamil Selvi Loganathan ◽  
Siti Aishah Sulaiman ◽  
Nor Azian Abdul Murad ◽  
Rahman Jamal ◽  
Noraidatulakma Abdullah
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Diabetes Patients

Long noncoding RNAs as novel biomarkers for Type 2 diabetes

2020 ◽  
Vol 14 (15) ◽  
pp. 1501-1511
Author(s):  
Han Zhu ◽  
Xiaolan Bian ◽  
Jingru Gong ◽  
Ping Yu ◽  
Huiping Lu
Keyword(s):  
Type 2 Diabetes ◽  
Cell Mass ◽  
Noncoding Rnas ◽  
Glucagon Secretion ◽  
Long Noncoding Rnas ◽  
Β Cell ◽  
Metabolic Markers ◽  
Novel Biomarkers ◽  
And Function

Type 2 diabetes (T2D) is a metabolic disease characterized by disordered glucagon secretion, insulin resistance in target tissues, and decreased islet β-cell mass and function. The routine diagnosis was based on measurements of metabolic markers, while genetic risk factors have been considered to increase the probability of predicting the development of the disease. Recent evidence suggests that long noncoding RNAs (lncRNAs) regulate gene expression in various physiological and pathological processes. As increasing lncRNAs are identified in β cells, understanding the regulatory roles of lncRNAs in T2D becomes indispensable. In this review, we discuss the potential role of lncRNAs contributing to β-cell identity and T2D susceptibility, which provide a perspective insight into the development of novel diagnosis biomarkers for T2D.

Sign in / Sign up

Export Citation Format

Share Document